While religion has too often been a tool of authoritarianism, faith communities have also been the life force of so many ...

In a phase 1b trial, tarlatamab plus an anti-PD-L1 in first-line maintenance achieves a median survival of more than 2 years ...

ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for ...

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer ...

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance ...

During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte ...

Small-cell lung cancer (SCLC) and some other cancers involve dysregulation of the transcription factor E2F, and apoptosis can be induced in those cells by blocking the interaction of the RxL sequence ...

Many cancer-driving mutations disable a key checkpoint in the cell’s cycle between growth and division, resulting in unchecked activity of the E2F family of transcription factor proteins. A set of ...

BeOne Medicines sells rights to Imdelltra sales, excluding China, to Royalty Pharma for up to $950 million, with an $885 million upfront payment. The agreement allows BeOne to retain royalties on ...

ABD-147 is a targeted radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to solid tumors expressing delta-like ligand 3 (DLL3) ...

Royalty Pharma to acquire rights to BeOne’s royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 million IMDELLTRA is a first-in-class DLL-3 targeting bispecific T-cell ...